This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.
Earnings Estimates Moving Higher for QIAGEN (QGEN): Time to Buy?
by Zacks Equity Research
QIAGEN (QGEN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt
by Zacks Equity Research
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff
by Zacks Equity Research
QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
How QIAGEN (QGEN) Stock Stands Out in a Strong Industry?
by Zacks Equity Research
QIAGEN (QGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
QGEN vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
5 Coronavirus-Proof PEG Picks Suitable for GARP Investors
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters amid coronavirus-led market rattle.
Can Qiagen (QGEN) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Qiagen (QGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across all geographies and each of its operating segments in Q1 despite the coronavirus-led economic crisis.
QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales
by Zacks Equity Research
QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.
QIAGEN Launches Assay for Cancer Patients Following FDA's Nod
by Zacks Equity Research
QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.
QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1
by Zacks Equity Research
Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. QGEN: Which Stock Is the Better Value Option?
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Healthcare Stocks & ETFs to Gain on Coronavirus Test Progress
by Sweta Jaiswal, FRM
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
Can Economic Stimulus Save MedTech From Coronavirus Doldrums?
by Trina Mukherjee
Following the announcement of the agreement to pass the historic stimulus bill, we look into four MedTech stocks that stand to gain from the same.
Varian Unveils Proton Treatment Planning Eclipse v16 System
by Zacks Equity Research
The launch of this system is a step forward in Varian's (VAR) commitment toward strengthening its Proton Solutions segment.
Abbott (ABT) Rides on Point-of-Care Coronavirus Test Launch
by Zacks Equity Research
Abbott (ABT) launches a portable molecular point-of-care test to speed up coronavirus detection, especially in areas with severe outbreaks.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its strong segmental results in the fourth quarter of 2019.
Medtronic's Evolut TAVR System Shows Positive Study Results
by Zacks Equity Research
Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.
4 MedTech Stocks Set to Rebound Post Coronavirus-Led Crisis
by Zacks Equity Research
Here are some MedTech stocks which are steadily inching toward a trend reversal after registering record declines over the past few weeks.